Carcinoma, Squamous Cell  >>  Caprelsa (vandetanib)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00404924 / 2006-002384-12: ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Checkmark P3 data (NSCLC) ZEPHYR
Mar 2012 - Mar 2012: P3 data (NSCLC) ZEPHYR
Completed
3
1140
US, Canada, Europe, RoW
ZD6474 (vandetanib), ZACTIMA™, Best Supportive Care
Genzyme, a Sanofi Company
Non-Small-Cell Lung Carcinoma
10/09
11/14

Download Options